Recursion Pharmaceuticals (RXRX) Non-Current Deferred Tax Liability (2023 - 2026)

Recursion Pharmaceuticals' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 18.51% year-over-year to $18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.3 million (down 18.51% YoY) and the FY2025 annual result came in at $23.3 million, down 74.63% from the prior year.
• Non-Current Deferred Tax Liability was $18.3 million for Q1 2026 at Recursion Pharmaceuticals, down from $23.3 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $91.7 million in Q4 2024 and bottomed at $168000.0 in Q3 2024.
• A 4-year average of $19.2 million and a median of $18.3 million in 2026 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability tumbled 91.3% — and 2025, when it surged 13776.19%.
• Recursion Pharmaceuticals' Non-Current Deferred Tax Liability stood at $1.3 million in 2023, then soared by 6746.98% to $91.7 million in 2024, then tumbled by 74.63% to $23.3 million in 2025, then decreased by 21.38% to $18.3 million in 2026.
• Business Quant data shows RXRX's Non-Current Deferred Tax Liability at $18.3 million in Q1 2026, $23.3 million in Q4 2025, and $23.3 million in Q3 2025.